Comparative Pharmacology
Head-to-head clinical analysis: BUTABARB versus SECOBARBITAL SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTABARB versus SECOBARBITAL SODIUM.
BUTABARB vs SECOBARBITAL SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Barbiturate that binds to GABA-A receptor subunits, potentiating GABAergic inhibition by increasing chloride ion conductance and reducing neuronal excitability.
Secobarbital enhances the activity of gamma-aminobutyric acid (GABA) at GABA-A receptors, increasing chloride ion influx and causing neuronal hyperpolarization, leading to CNS depression.
15-30 mg orally 3-4 times daily as needed; maximum 200 mg/day. IV/IM: 50-200 mg for sedation.
Oral: 100-200 mg at bedtime for insomnia; IM: 150-200 mg as a single dose; IV: 50-250 mg as a single dose, administered slowly (not to exceed 50 mg per 15 seconds).
None Documented
None Documented
Terminal elimination half-life is 30-60 hours (mean ~40 hours) in adults with normal renal and hepatic function. Longer in elderly or patients with liver disease.
Clinical Note
moderateButabarbital + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Butabarbital is combined with Fluticasone propionate."
Clinical Note
moderateButabarbital + Haloperidol
"The risk or severity of adverse effects can be increased when Butabarbital is combined with Haloperidol."
Clinical Note
moderateButabarbital + Clemastine
"The risk or severity of adverse effects can be increased when Butabarbital is combined with Clemastine."
Clinical Note
moderateTerminal elimination half-life is approximately 15-40 hours (mean ~30 hours) in adults. In neonates, half-life may be prolonged (up to 100 hours). Half-life increases in hepatic impairment and with advanced age.
Renal excretion of unchanged drug and metabolites. Approximately 70-80% of a dose is eliminated in urine as metabolites (hydroxy and glucuronide conjugates) and <5% as parent drug. Minimal biliary/fecal elimination (<5%).
Renal excretion of unchanged drug (about 25-50%) and metabolites; the remainder is eliminated via hepatic metabolism and fecal excretion. Less than 5% is excreted unchanged in feces.
Category C
Category D/X
Barbiturate
Barbiturate
Butabarbital + Venlafaxine
"The risk or severity of adverse effects can be increased when Butabarbital is combined with Venlafaxine."